Treatment of Ventilator-Associated Pneumonia Without Risk Factors for Antimicrobial Resistance
Clinical Scenario
This protocol applies to patients with suspected or confirmed ventilator-associated pneumonia (VAP) who have no identified risk factors for antimicrobial resistance, managed in an ICU where local resistance rates fall below key thresholds.
S. aureus MRSA rate <10%–20%
Gram-negative resistance to monotherapy agent ≤10%
Antibiotic Selection Rationale
In this low-resistance ICU setting, empiric coverage can be directed against methicillin-susceptible S. aureus (MSSA) rather than MRSA. For gram-negative coverage, a single agent active against Pseudomonas aeruginosa is appropriate for monotherapy when local resistance rates support this choice — combination gram-negative coverage is not required.
When Systemic Therapy Is Insufficient
For patients whose VAP does not respond adequately to intravenous antibiotics alone, adjunctive inhaled antibiotic therapy may be considered as a treatment of last resort, added to the systemic regimen.
The specific agents, indications, and complete regimen details are available in the structured protocol below.
References
- We suggest including an agent active against MSSA (and not MRSA) for the empiric treatment of suspected VAP in patients without risk factors for antimicrobial resistance, who are being treated in ICUs where <10%–20% of S. aureus isolates are methicillin resistant (weak recommendation, very low-quality evidence).
- We suggest prescribing one antibiotic active against P. aeruginosa for the empiric treatment of suspected VAP in patients without risk factors for antimicrobial resistance who are being treated in ICUs where ≤10% of gram-negative isolates are resistant to the agent being considered for monotherapy (weak recommendation, low-quality evidence).
- For patients with VAP due to gram-negative bacilli that are susceptible to only aminoglycosides or polymyxins (colistin or polymyxin B), we suggest both inhaled and systemic antibiotics, rather than systemic antibiotics alone (weak recommendation, very low-quality evidence).
- It is reasonable to consider adjunctive inhaled antibiotic therapy as a treatment of last resort for patients who are not responding to intravenous antibiotics alone, whether the infecting organism is or is not MDR.
DOI: 10.1093/cid/ciw353
View source ↗